A Phase 3, randomized, non-inferiority study of a heterologous booster dose of SARS CoV-2 recombinant spike protein vaccine in adults

Due to waning immunity following primary immunization with COVID-19 vaccines, booster doses may be required. The present study assessed a heterologous booster of SII-NVX-CoV2373 (spike protein vaccine) in adults primed with viral vector and inactivated vaccines. In this Phase 3, observer-blind, rand...

Descripción completa

Detalles Bibliográficos
Autores principales: Kulkarni, Prasad S., Gunale, Bhagwat, Kohli, Sunil, Lalwani, Sanjay, Tripathy, Srikanth, Kar, Sonali, Raut, Sidram, Kulkarni, Praveen, Apte, Aditi, Bavdekar, Ashish, Bhalla, Hira Lal, Plested, Joyce S., Cloney-Clark, Shane, Zhu, MingZhu, Kalkeri, Raj, Pryor, Melinda, Hamilton, Stephanie, Thakar, Madhuri, Sannidhi, Ranga S., Baranwal, Punjita, Bhamare, Chetanraj, Dharmadhikari, Abhijeet, Gupta, Manish, Poonawalla, Cyrus S., Shaligram, Umesh, Kapse, Dhananjay
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10547846/
https://www.ncbi.nlm.nih.gov/pubmed/37789040
http://dx.doi.org/10.1038/s41598-023-43578-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10547846/
https://www.ncbi.nlm.nih.gov/pubmed/37789040
http://dx.doi.org/10.1038/s41598-023-43578-w

Ejemplares similares